Gene · 58508
Papers4,204
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
381 to 400 of 4,204
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The clinical features and prognostic implications of PTPN11 mutation in adult patients with acute myeloid leukemia in China. | Cancer Med | 2023 | 37937729 | PubTator, text mining | PubMed |
| Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy. | Br J Cancer | 2023 | 37935787 | PubTator, text mining | PubMed |
| MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer. | Cell Biosci | 2023 | 37932806 | PubTator, text mining | PubMed |
| Mesenchymal stem cells under epigenetic control - the role of epigenetic machinery in fate decision and functional properties. | Cell Death Dis | 2023 | 37932257 | PubTator, text mining | PubMed |
| Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study. | Elife | 2023 | 37929934 | PubTator, text mining | PubMed |
| Implant replacement and anaplastic large cell lymphoma associated with breast implants: a quantitative analysis. | Front Oncol | 2023 | 37927474 | PubTator, text mining | PubMed |
| Whole exome sequencing identifies common mutational landscape of cervix and endometrium small cell neuroendocrine carcinoma. | Front Oncol | 2023 | 37920164 | PubTator, text mining | PubMed |
| Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer. | NPJ Precis Oncol | 2023 | 37919480 | PubTator, text mining | PubMed |
| Systematic analysis of copy number variants of uncertain significance partially overlapping with the haploinsufficient or triplosensitive genes in clinical testing. | Ann Med | 2023 | 37917952 | PubTator, text mining | PubMed |
| Advanced renal pelvis carcinoma patient with an ERBB2 insertion mutation: a case report. | J Int Med Res | 2023 | 37917812 | PubTator, text mining | PubMed |
| Rational therapeutic targets with biomolecular liquid-liquid phase separation regulating synergy: A pan-cancer analysis. | PLoS One | 2023 | 37917664 | PubTator, text mining | PubMed |
| Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321). | Front Oncol | 2023 | 37909020 | PubTator, text mining | PubMed |
| Clinical Features and Outcomes of Primary Breast Diffuse Large B-Cell Lymphoma: A Matched-Pair Study. | Clin Med Insights Oncol | 2023 | 37905234 | PubTator, text mining | PubMed |
| Seven chromatin regulators as immune cell infiltration characteristics, potential diagnostic biomarkers and drugs prediction in hepatocellular carcinoma. | Sci Rep | 2023 | 37903974 | PubTator, text mining | PubMed |
| Isoform-resolved transcriptome of the human preimplantation embryo. | Nat Commun | 2023 | 37903791 | PubTator, text mining | PubMed |
| The microbiome and rise of early-onset cancers: knowledge gaps and research opportunities. | Gut Microbes | 2023 | 37902043 | PubTator, text mining | PubMed |
| The RNA m6A-Binding Protein YTHDC1 Is Downregulated and Associated With M2 Macrophage Infiltration in Muscle-Invasive Bladder Cancer. | Clin Med Insights Oncol | 2023 | 37901254 | PubTator, text mining | PubMed |
| EVI1 Disruption Post Neuroblastoma Treatment: A Case Analysis of Treatment-Associated Acute Myeloid Leukemia in a Pediatric Patient. | Case Rep Oncol | 2023 | 37900834 | PubTator, text mining | PubMed |
| Mutations in a High-Grade Micropapillary Urothelial Carcinoma of the Renal Pelvis: A Case Report. | Case Rep Oncol | 2023 | 37900819 | PubTator, text mining | PubMed |
| Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases. | J Neurooncol | 2023 | 37897649 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/58508/papers?page=20